Clinical Trials Logo

Clinical Trial Summary

This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04476706
Study type Expanded Access
Source Novartis
Contact
Status No longer available
Phase